<DOC>
	<DOCNO>NCT00805714</DOCNO>
	<brief_summary>Statins usually use AMI patient due strong anti-lipidemic effect , pleiotropic effect tolerable safety profile . Generally AMI patient prescribe many drug concomitantly ; risk due drug interaction . Especially , statin report many drug interaction , might influence therapeutic prognosis safety AMI patient . This study conduct administer non-CYP3A4 metabolized statin , pitavastatin AMI patient 1 year , result compare result KAMIR study expect large scale AMI patient use statin enrol . Finally , comparison , investigate influence statin metabolism CYP3A4 therapeutic prognosis like death , major adverse cardiac event ( MACE ) , major ADR statin like CK increase , myalgia .</brief_summary>
	<brief_title>Livalo Acute Myocardial Infarction Study</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>The patient take pitavastatin since AMI</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Hydroxymethylglutaryl-CoA Reductase Inhibitors</keyword>
</DOC>